NCT06333977View on ClinicalTrials.gov

A Study of LC542019 in Healthy Subjects and Subjects With T2DM

PHASE1CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

March 25, 2022

Primary Completion Date

December 14, 2023

Study Completion Date

December 14, 2023

Conditions

HealthyDiabetes Mellitus, Type 2

Interventions

DRUG

LC542019

oral dose, once daily

DRUG

Placebo

matching placebo

Trial Locations (1)

89113

PPD Development, LP (PPD Clinical Research Unit, Las Vegas), Las Vegas

Sponsors

Lead Sponsor

All Listed Sponsors

lead

LG Chem

INDUSTRY

NCT06333977 - A Study of LC542019 in Healthy Subjects and Subjects With T2DM | Biotech Hunter | Biotech Hunter